# NCT04221542 (NCT04221542)

> Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: xaluritamig (AMG 509); xaluritamig (AMG 509) plus abiraterone; xaluritamig (AMG 509) plus enzalutamide
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04221542
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Amgen
- Conditions: Prostate Cancer
- Interventions: AMG 509; Abiraterone; Enzalutamide
- Enrollment: 479
- Primary outcome: Parts 1-5 and 7: Incidence of Treatment-emergent Adverse Events
- Primary outcome: Parts 1-5 and 7: Incidence of Treatment-related Adverse Events
- Primary outcome: Parts 1-5 and 7 Dose Exploration Cohorts Only: Dose Limiting Toxicities (DLTs)
- Primary outcome: Parts 1-5 and 7: Number of Participants with Changes in Vital Signs
- Primary outcome: Parts 1-5 and 7: Number of Participants with Changes in Electrocardiogram (ECG) Records
- Primary outcome: Parts 1-5 and 7: Number of Participants with Changes in Clinical Laboratory Test Results
- Primary outcome: Part 6: Objective Response (OR) per RECIST v1.1

## Indexed commentary on NCT04221542 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04221542